Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL
Abstract. Chimeric antigen receptor (CAR)-modified T-cell therapy has revolutionized the care of patients with relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL). Results from clinical trials across multiple institutions report remarkable remission rates with CD19-directed CAR-modif...
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Wiley
2019-08-01
|
| Reeks: | HemaSphere |
| Online toegang: | http://journals.lww.com/10.1097/HS9.0000000000000279 |